No, oseltamivir should NOT be given to a postpartum patient with RSV infection
Oseltamivir is a neuraminidase inhibitor that is only effective against influenza viruses (influenza A and B), and has no activity against respiratory syncytial virus (RSV). 1
Why Oseltamivir Does Not Work for RSV
Oseltamivir's mechanism of action targets the neuraminidase enzyme found on influenza viruses, which RSV does not possess. The FDA labeling for oseltamivir clearly indicates its use is limited to treatment and prophylaxis of influenza only 1. There is no biological rationale or evidence supporting its use for RSV infection.
What Should Be Used for RSV Instead
For RSV treatment in immunocompromised or high-risk patients (such as hematopoietic stem cell transplant recipients), the available options include 2:
- Aerosolized ribavirin: 2 g for 2 hours every 8 hours OR 6 g over 18 hours daily for 7-10 days
- Systemic ribavirin: Oral or intravenous (10-30 mg/kg body weight in 3 divided doses)
- Supportive care remains the mainstay for most immunocompetent patients, including postpartum women
Important Clinical Caveat
The key clinical pitfall here is misdiagnosing the viral pathogen. If a postpartum patient presents with respiratory symptoms during flu season, it is critical to:
- Obtain proper diagnostic testing to differentiate influenza from RSV 2
- Use multiplex PCR or rapid antigen testing for both viruses
- Not empirically treat with oseltamivir assuming all respiratory viral illnesses are influenza
Safety in Postpartum Women
While oseltamivir is safe in postpartum and breastfeeding women (present in breast milk at low levels unlikely to cause toxicity) 1, 3, this safety profile is irrelevant when treating RSV since the drug has no antiviral activity against this pathogen.
Bottom line: Confirm the viral diagnosis first. If RSV is confirmed, oseltamivir provides no benefit and should not be prescribed. Focus on supportive care for immunocompetent postpartum patients with RSV.